These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 11926817

  • 1. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin-2 receptor.
    Giragossian C, Mierke DF.
    Biochemistry; 2002 Apr 09; 41(14):4560-6. PubMed ID: 11926817
    [Abstract] [Full Text] [Related]

  • 2. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin A receptor.
    Giragossian C, Mierke DF.
    Biochemistry; 2001 Apr 03; 40(13):3804-9. PubMed ID: 11300760
    [Abstract] [Full Text] [Related]

  • 3. Conformational and molecular modeling studies of sulfated cholecystokinin-15.
    Giragossian C, Stone S, Papini AM, Moroder L, Mierke DF.
    Biochem Biophys Res Commun; 2002 May 10; 293(3):1053-9. PubMed ID: 12051766
    [Abstract] [Full Text] [Related]

  • 4. Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor.
    Giragossian C, Sugg EE, Szewczyk JR, Mierke DF.
    J Med Chem; 2003 Jul 31; 46(16):3476-82. PubMed ID: 12877585
    [Abstract] [Full Text] [Related]

  • 5. Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy.
    Pellegrini M, Mierke DF.
    Biochemistry; 1999 Nov 09; 38(45):14775-83. PubMed ID: 10555959
    [Abstract] [Full Text] [Related]

  • 6. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
    Stone SR, Giragossian C, Mierke DF, Jackson GE.
    Peptides; 2007 Nov 09; 28(11):2211-22. PubMed ID: 17950490
    [Abstract] [Full Text] [Related]

  • 7. Determination of ligand-receptor interactions of cholecystokinin by nuclear magnetic resonance.
    Giragossian C, Mierke DF.
    Life Sci; 2003 Jun 27; 73(6):705-13. PubMed ID: 12801592
    [Abstract] [Full Text] [Related]

  • 8. Conformational and molecular modeling studies of beta-cyclodextrin-heptagastrin and the third extracellular loop of the cholecystokinin 2 receptor.
    Giragossian C, Schaschke N, Moroder L, Mierke DF.
    Biochemistry; 2004 Mar 16; 43(10):2724-31. PubMed ID: 15005607
    [Abstract] [Full Text] [Related]

  • 9. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ.
    J Med Chem; 1996 Sep 27; 39(20):4120-4. PubMed ID: 8831778
    [Abstract] [Full Text] [Related]

  • 10. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ.
    Mol Pharmacol; 2004 Jan 27; 65(1):28-35. PubMed ID: 14722234
    [Abstract] [Full Text] [Related]

  • 11. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.
    Laverman P, Béhé M, Oyen WJ, Willems PH, Corstens FH, Behr TM, Boerman OC.
    Bioconjug Chem; 2004 Jan 27; 15(3):561-8. PubMed ID: 15149184
    [Abstract] [Full Text] [Related]

  • 12. Environmental mimic of receptor interaction: conformational analysis of CCK-15 in solution.
    Albrizio S, Carotenuto A, Fattorusso C, Moroder L, Picone D, Temussi PA, D'Ursi A.
    J Med Chem; 2002 Feb 14; 45(4):762-9. PubMed ID: 11831889
    [Abstract] [Full Text] [Related]

  • 13. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C, Gigoux V, Archer E, Verrier S, Maigret B, Behrendt R, Moroder L, Bignon E, Silvente-Poirot S, Pradayrol L, Fourmy D.
    J Biol Chem; 2002 Mar 01; 277(9):7546-55. PubMed ID: 11724786
    [Abstract] [Full Text] [Related]

  • 14. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
    Foucaud M, Archer-Lahlou E, Marco E, Tikhonova IG, Maigret B, Escrieut C, Langer I, Fourmy D.
    Regul Pept; 2008 Jan 10; 145(1-3):17-23. PubMed ID: 17961734
    [Abstract] [Full Text] [Related]

  • 15. Fluorescence studies on the binding between 1-47 fragment of cholecystokinin receptor CCK(A)-R(1-47) and nonsulfated cholecystokinin octapeptide CCK8.
    Ragone R, De Luca S, Tesauro D, Pedone C, Morelli G.
    Biopolymers; 2008 Jan 10; 56(1):47-53. PubMed ID: 11582577
    [Abstract] [Full Text] [Related]

  • 16. The role of segment 32-47 of cholecystokinin receptor type A in CCK8 binding: synthesis, nuclear magnetic resonance, circular dichroism and fluorescence studies.
    De Luca S, Ragone R, Bracco C, Digilio G, Tesauro D, Saviano M, Pedone C, Morelli G.
    J Pept Sci; 2003 Mar 10; 9(3):156-69. PubMed ID: 12675498
    [Abstract] [Full Text] [Related]

  • 17. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
    Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Fréhel D, Gully D, Vaysse N, Fourmy D.
    J Biol Chem; 1997 Jan 31; 272(5):2920-6. PubMed ID: 9006937
    [Abstract] [Full Text] [Related]

  • 18. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.
    Fourmy D, Escrieut C, Archer E, Galès C, Gigoux V, Maigret B, Moroder L, Silvente-Poirot S, Martinez J, Fehrentz JA, Pradayrol L.
    Pharmacol Toxicol; 2002 Dec 31; 91(6):313-20. PubMed ID: 12688374
    [Abstract] [Full Text] [Related]

  • 19. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
    De Luca S, Saviano M, Della Moglie R, Digilio G, Bracco C, Aloj L, Tarallo L, Pedone C, Morelli G.
    ChemMedChem; 2006 Sep 31; 1(9):997-1006. PubMed ID: 16915602
    [Abstract] [Full Text] [Related]

  • 20. Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity.
    Ren Y, Bläker M, Seshadri L, McBride EW, Beinborn M, Kopin AS.
    J Mol Neurosci; 2003 Apr 31; 20(2):115-24. PubMed ID: 12794305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.